OSR Holdings, Inc. (OSRH)
NASDAQ: OSRH · Real-Time Price · USD
1.050
-0.010 (-0.94%)
At close: Jul 16, 2025, 4:00 PM
1.060
+0.010 (0.95%)
After-hours: Jul 16, 2025, 7:58 PM EDT

Company Description

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea.

The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.

It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis.

In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.

OSR Holdings, Inc.
OSR Holdings logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees21
CEOKuk Hwang

Contact Details

Address:
10900 NE 4th Street, Suite 2300
Bellevue, Washington 98004
United States
Phone425-635-7700
Websiteosr-holdings.com

Stock Details

Ticker SymbolOSRH
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001840425
ISIN NumberUS68840D1028

Key Executives

NamePosition
Kuk Hyoun HwangChairman and Chief Executive Officer
Gihyoun BangChief Financial Officer
Sang Hoon KimHead of Corporate Venture Capital
Dr. Constance HoferChief Scientific Officer
Jun Chul WhangChief Legal Officer, Secretary and Director